{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:59:42Z","timestamp":1766415582841,"version":"3.48.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gore.2025.101803","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:21:28Z","timestamp":1752614488000},"page":"101803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ivermectin and Gynecologic Cancer: What are the data?"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-6667","authenticated-orcid":false,"given":"Vaidehi","family":"Mujumdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey Chippendale","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Musa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2025.101803_b0005","unstructured":"\u201cFind NCI-Supported Clinical Trials.\u201d National Cancer Institute , www.cancer.gov\/research\/participate\/clinical-trials-search. (Accessed 29 May 2025)."},{"key":"10.1016\/j.gore.2025.101803_b0010","unstructured":"A Phase I\/Ii Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with Expansion Cohort in Pd-L1 Negative Tnbc. Translated by Inc Agenus and Research Gateway for Cancer, 2022. Accessed May 18, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05318469?cond=ivermectin%20cancer&rank=2."},{"key":"10.1016\/j.gore.2025.101803_b0015","unstructured":"Blum, D. What Ivermectin Can (and Can\u2019t) Do. The New York Times , Published March 31 2025, Accessed June 5, 2025. www.nytimes.com\/2025\/03\/31\/well\/ivermectin-cancer-covid.html."},{"issue":"2","key":"10.1016\/j.gore.2025.101803_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, 'wonder drug' from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"1","key":"10.1016\/j.gore.2025.101803_b0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13256-023-03891-4","article-title":"Successful management of poisoning with ivermectin (Mectizan) in the Obala health district (Centre Region, Cameroon): a case report","volume":"17","author":"Donfo-Azafack","year":"2023","journal-title":"J. Med. Case Reports"},{"issue":"7","key":"10.1016\/j.gore.2025.101803_b0035","article-title":"Identifying the toxidrome of ivermectin toxicity","volume":"15","author":"Dy","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.gore.2025.101803_b0040","unstructured":"U.S. Food and Drug Administration. Ivermectin and COVID-19. Published April 5, 2024, Accessed May 18, 2025. https:\/\/www.fda.gov\/consumers\/consumer-updates\/ivermectin-and-covid-19."},{"issue":"6","key":"10.1016\/j.gore.2025.101803_b0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/0018578718758972","article-title":"A case of ivermectin-induced warfarin toxicity: first published report","volume":"53","author":"Gilbert","year":"2018","journal-title":"Hosp. Pharm."},{"issue":"6","key":"10.1016\/j.gore.2025.101803_b0050","first-page":"243","article-title":"Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines","volume":"3","author":"Hashimoto","year":"2009","journal-title":"Drug. Discov. Ther."},{"issue":"4","key":"10.1016\/j.gore.2025.101803_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106130","article-title":"Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes","volume":"88","author":"Hayward","year":"2024","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/j.gore.2025.101803_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/diseases11010049","article-title":"Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells","volume":"11","author":"Jawad","year":"2023","journal-title":"Diseases"},{"issue":"1","key":"10.1016\/j.gore.2025.101803_b0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.gore.2025.101803_b0070","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/15563650.2022.2043338","article-title":"Ivermectin: a mini-review","volume":"60","author":"Johnson-Arbor","year":"2022","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.gore.2025.101803_b0075","unstructured":"Lawrence, L. Interest in Ivermectin for Cancer \u2018Has Spread like Wildfire,\u2019 Oncologists Say, Published June 13, 2025, (Accessed July 5, 2025) www.oncologynewscentral.com\/oncology\/interest-in-ivermectin-for-cancer-has-spread-like-wildfire-oncologists-say."},{"key":"10.1016\/j.gore.2025.101803_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934746","article-title":"Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction","volume":"13","author":"Lee","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.gore.2025.101803_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.954","article-title":"Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways","volume":"10","author":"Lu","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.gore.2025.101803_b0020","unstructured":"Mayo Clinic. Ivermectin (Oral Route) Description and Brand Names - Mayo Clinic. www.mayoclinic.org. Published February 1, 2025. Accessed May 18, 2025. https:\/\/www.mayoclinic.org\/drugs-supplements\/ivermectin-oral-route\/description\/drg-20064397."},{"issue":"11","key":"10.1016\/j.gore.2025.101803_b0090","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.2023.1650","article-title":"Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial","volume":"329","author":"Naggie","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gore.2025.101803_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010014","article-title":"Ivermectin strengthens paclitaxel effectiveness in high-grade serous carcinoma in 3D cell cultures","volume":"18","author":"Nunes","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.gore.2025.101803_b0100","unstructured":"Office for Human Research Protections (OHRP). \u201c45 CFR 46.\u201d HHS.Gov, 12 Feb. 2025, www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/45-cfr-46\/index.html."},{"issue":"18","key":"10.1016\/j.gore.2025.101803_b0105","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with Covid-19","volume":"386","author":"Reis","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.gore.2025.101803_b0110","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00204-021-03025-z","article-title":"Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects","volume":"95","author":"Rendic","year":"2021","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.gore.2025.101803_b0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1377\/hlthaff.2024.00452","article-title":"Demographic variation In US outpatient hydroxychloroquine and ivermectin use during the COVID-19 pandemic","volume":"44","author":"Rockwell","year":"2025","journal-title":"Health Aff (millwood)"},{"key":"10.1016\/j.gore.2025.101803_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2021.100924","article-title":"Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19","volume":"43","author":"Santin","year":"2021","journal-title":"New Microb. New Infect."},{"issue":"3","key":"10.1016\/j.gore.2025.101803_b0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2025.101803_b0130","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ANDA NDA 204154. Retrieved May 18, 2025, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204154Orig1s000lbl.pdf."},{"key":"10.1016\/j.gore.2025.101803_b0135","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Sklice NDA 202736. Retrieved May 18, 2025, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204154Orig1s000lbl.pdf."},{"issue":"33","key":"10.1016\/j.gore.2025.101803_b0140","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.gore.2025.101803_b0145","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1080\/15548627.2016.1231494","article-title":"Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer","volume":"12","author":"Wang","year":"2016","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.gore.2025.101803_b0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41429-021-00491-6","article-title":"The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review","volume":"75","author":"Zaidi","year":"2022","journal-title":"J. Antibiot."},{"issue":"2","key":"10.1016\/j.gore.2025.101803_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt\/mTOR signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am. J. Med. Sci."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925001286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:18:47Z","timestamp":1766413127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925001286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"alternative-id":["S2352578925001286"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101803","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivermectin and Gynecologic Cancer: What are the data?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101803"}}